Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
TRECONY study of CHF5993 propellant formulations in mild to moderate asthma
2025-521456-35-00Phase 2Authorised
- Sponsor
- Chiesi Farmaceutici S.p.A.
- Start
- Apr 2026
- Modality
- Small Molecules
- Countries
- 15
01
Overview
Phase 2, randomised, double-blind trial of beclometasone dipropionate/formoterol fumarate/glycopyrronium in asthma (3 arms), sponsored by Chiesi Farmaceutici S.p.A. Primary endpoints: Change from baseline in FEV1 AUC0-4h on Day 1 and Change from baseline in pre-dose FEV1 on Day 28. Planned start Apr 2026; status: authorised.
02
Drugs
beclometasone dipropionate/formoterol fumarate/glycopyrronium
03
Conditions
asthma
Beyond the preview
Go deeper on 2025-521456-35-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2025-521456-35-00.